Plasmodium is a genus of single-celled parasites that cause malaria, one of the most consequential infectious diseases in human history. These microscopic organisms cycle between mosquitoes and vertebrate hosts, invading liver cells and red blood cells to reproduce. In 2023 alone, Plasmodium parasites were responsible for an estimated 263 million malaria cases and 597,000 deaths worldwide, with roughly 95% of those deaths occurring in Africa.
What Kind of Organism Is Plasmodium?
Plasmodium belongs to a large group of parasites called Apicomplexa, nearly all of which are obligate parasites, meaning they cannot survive outside a host. This group sits within a broader family tree that also includes dinoflagellates and ciliates, both free-living organisms found in water. What sets Plasmodium and its apicomplexan relatives apart is a structure called the apicoplast: a tiny, non-functional remnant of what was once a photosynthetic organ, similar to chloroplasts in plants. In other words, the ancestors of malaria parasites were likely once capable of photosynthesis, but over evolutionary time they shifted entirely to a parasitic lifestyle.
Each Plasmodium cell carries three separate sets of genetic material: one in the nucleus, one in a mitochondrion, and one in the apicoplast. The apicoplast genome is the smallest of any known plastid. Throughout the stages spent inside a human host, the parasite’s cells are haploid, carrying only a single copy of each chromosome. Sexual reproduction, which produces the only diploid stage, happens exclusively inside the mosquito.
Species That Infect Humans
Five Plasmodium species regularly cause malaria in people. They differ in severity, geographic range, and behavior inside the body.
P. falciparum is the deadliest. It’s the dominant species in sub-Saharan Africa and causes the vast majority of malaria deaths. It belongs to a separate subgenus called Laverania, which originally evolved in great apes. P. falciparum infections tend to have shorter incubation periods, sometimes as few as 7 days, and can progress rapidly to life-threatening complications.
P. vivax is the most geographically widespread species and the leading cause of malaria outside Africa, particularly in South and Southeast Asia and Latin America. It has a distinctive trick: it can form dormant stages called hypnozoites that hide in liver cells for months or even years, then reactivate to cause relapses long after the initial infection clears.
P. ovale also produces hypnozoites and can cause relapses. It’s found mainly in West Africa and is generally less common. P. malariae tends to have the longest incubation period, up to 30 days, and causes a milder but persistent form of malaria. P. knowlesi, originally a parasite of macaque monkeys in Southeast Asia, has been increasingly recognized as a cause of human malaria in forested regions of that area. It replicates quickly in the blood and can become dangerous if not treated promptly.
Life Cycle in the Human Body
Plasmodium’s life cycle is remarkably complex, requiring two hosts to complete. When an infected female Anopheles mosquito bites a person, it injects parasites in a form called sporozoites into the skin. These sporozoites travel through the bloodstream to the liver, where they invade liver cells and begin multiplying. Over the next several days, a single sporozoite can produce thousands of new parasites called merozoites inside a liver cell.
When the liver cell bursts, those merozoites flood into the bloodstream and begin invading red blood cells. Inside each red blood cell, the parasite feeds on hemoglobin, grows, and divides again. When the red blood cell ruptures, a new wave of merozoites is released to infect more red blood cells. This cycle of invasion, replication, and rupture repeats every 48 to 72 hours depending on the species, and it’s this synchronized destruction of red blood cells that produces the classic waves of fever, chills, and sweating associated with malaria.
Some parasites in the blood take a different path. Instead of continuing to replicate, they develop into sexual forms called gametocytes. These don’t cause symptoms directly, but they’re the key to transmission: when a mosquito bites an infected person and picks up gametocytes, the cycle continues in the insect.
Life Cycle in the Mosquito
Inside the mosquito’s gut, male and female gametocytes transform into gametes that fuse to create a zygote. This is the only point in the entire life cycle where the parasite is diploid. Within about 24 hours, the zygote becomes a motile form called an ookinete, which burrows through the mosquito’s gut wall and settles on the outer surface to form a cyst called an oocyst.
Over the next 6 to 12 days, the oocyst grows considerably, undergoing multiple rounds of DNA replication. Eventually it ruptures, releasing thousands of sporozoites into the mosquito’s body cavity. These sporozoites migrate to the salivary glands, where they wait to be injected into the next person the mosquito bites. The mosquito’s immune system does fight back, killing some parasites with complement-like proteins, but enough typically survive to maintain transmission.
How Plasmodium Causes Disease
The symptoms of malaria come almost entirely from the blood stage of infection. The liver stage is silent. Once merozoites are cycling through red blood cells, the body experiences damage through several mechanisms at once.
The most straightforward is anemia. Plasmodium destroys red blood cells directly when merozoites burst out of them, but the parasite also damages uninfected red blood cells by altering their membranes. On top of that, the body’s own red blood cell production becomes impaired during infection, a process called dyserythropoiesis. The spleen, which filters damaged cells from the blood, enlarges dramatically as it sequesters large numbers of red blood cells, worsening the anemia.
P. falciparum causes especially severe disease because of a process called cytoadherence. The parasite places proteins on the surface of infected red blood cells, creating thousands of tiny raised bumps called knobs. These knobs act like sticky anchors, causing infected red blood cells to cling to the walls of small blood vessels throughout the body. This is what makes falciparum malaria so dangerous: when infected cells stick to blood vessels in the brain, it can cause cerebral malaria. When they clog vessels in the lungs, kidneys, or placenta, organ damage follows. Other Plasmodium species generally don’t cause this kind of vascular obstruction, which is a major reason P. falciparum is so much more lethal.
Dormant Liver Stages and Relapse
P. vivax and P. ovale have a feature the other species lack: the ability to form hypnozoites, dormant parasites that remain quietly inside liver cells after the initial infection is cleared. These hypnozoites can reactivate weeks, months, or even years later, releasing a fresh wave of merozoites into the blood and causing a full relapse of symptoms. This makes these species particularly tricky for travelers, who may feel fine for months after leaving a malaria-endemic area before suddenly falling ill. Preventive medications can sometimes delay but not prevent reactivation if the dormant stages aren’t specifically targeted during treatment.
Drug Resistance
One of the most pressing challenges in fighting Plasmodium is the parasite’s ability to evolve resistance to drugs. The current frontline treatments for malaria are artemisinin-based combination therapies, which pair a fast-acting compound with a slower-acting partner drug. Partial resistance to artemisinin has now been confirmed in the Greater Mekong subregion of Southeast Asia, and in several African countries including Eritrea, Rwanda, Uganda, and Tanzania. Additional resistance is suspected in Ethiopia, Namibia, Sudan, and Zambia.
Artemisinin partial resistance alone rarely causes complete treatment failure, because the partner drug can still clear remaining parasites. But in the Greater Mekong subregion, resistance to partner drugs has also emerged, creating a situation where standard combinations may not work. The independent emergence of resistance in multiple locations, rather than resistance spreading from a single source, suggests that Plasmodium populations are under strong enough drug pressure to evolve resistance repeatedly, making surveillance and the development of new treatments a constant priority.
Global Burden
Since 2000, coordinated global efforts including insecticide-treated bed nets, indoor spraying, rapid diagnostic tests, and effective drugs have averted an estimated 2.2 billion malaria cases and 12.7 million deaths. Yet the disease remains a serious threat. The 263 million cases recorded in 2023 represented about 11 million more cases than the previous year, while deaths held roughly steady at 597,000. The overwhelming concentration of mortality in Africa reflects both the dominance of P. falciparum on the continent and gaps in access to prevention and treatment. Young children and pregnant women bear the heaviest burden, as they have the least immunity and the most vulnerability to severe anemia and organ damage.